The Global Acute-Migraine Treatment Industry is poised for unprecedented expansion, with a projected valuation of US$ 8.6 billion by the year 2032, boasting a Compound Annual Growth Rate (CAGR) of 4.9% from 2022 to 2032. This surge follows an already impressive trajectory, with the market expected to reach US$ 2.4 billion by the end of 2022.
Acute Migraine Treatment: Market Insights
Acute Migraine is an episodic, unpredictable headache disorder that is characterized by recurrent attacks. Migraine is the third most prevalent disease worldwide. Acute migraine causes severe throbbing pain and pulsing sensation usually on one side of the head. People with acuter migraine have headaches for 14 days a month. People with Acute migraine have fewer headaches a month than people with chronic one. Despite the vast number of migraine cases, only a small percentage of people go for the checkup.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-9324
However, growing awareness the emergence of new therapies for the treatment of migraine will significantly increase the market for acute migraine treatment shortly. More than hundreds of clinical trials underundergoing the acute migraine treatment with more than twetrialsrial arethe phase 4 which will create ate huge opportunity for the acute migraine treatment industry to rapidly grow in the forecast period. Currently, there is a limited number of pharmacological options available for acute migraine treatment such as triptans, NSAIDs,s, etc. Furthermore ore, the development of neprovidesprovide huge potential for the acute migraine treatment industry to fuel in the forecast period.
Acute Migraine Treatment: Market Dynamics
Rising number of population, growing prevalence of migraine is expected to drive the market of acute migraine treatment in the forecast period. Increasing number of female population as the disease is more prevalent in the females further accelerate the growth of the acute migraine treatment industry. Growing healthcare expenditure, rising adoption of unhealthy lifestyles, and growing awareness regarding acute migraine and its treatment further spur the market of acute migraine treatment globally.
However, stringent regulation for the drug approval, high cost of treatment, adverse side effect, lack of proper diagnosis and growing preference alternative time therapies are some of the facthinderingnder the growth of the acute migraine treatment industry
Acute Migraine Treatment: Overview
The emergence of new drugs and therapies for acute migraine treatment is expected to account for the significant growth of acute migraine treatment in the forecast The development of new drugs such as CGRP antagoprovides provides huge potential for the Global Acute Migraine Treatment Industry to grow. The development of new drugs by key pharmaceutical players such as Amgen, Novartis, Eli Lily, and Company and increasing research and development funding will create a huge opportunity for the market to grow shortly. For instance, in 2017, Eli Lilly and Company’s drug for acute migraine treatment succeeded in a key late-stage study, setting the stage for regulatory approval in the US
Methodology Details Just a Click Away!
https://www.futuremarketinsights.com/checkout/9324
Acute Migraine Treatment: Region-wise Out
The North America is expected to contribute to a major share the global acute migraine treatment, duthe e to the growing prevalence of acute migraine along with the increasing funding for the development of drugs with the presence of major pharmaceutical industries. According to the Migraine Research Foundation, 39 million of the US population suffer from migraine and 1 billion population worldwide. 18% of women, 6% of men, and 10% of children suffer from migraines. In 2015, the medical cost of treating migraine was more than $5.4 billion, although migraine patients spent over $41 billion on treating the entire range of migraine.
Europe accounts for the second largest market share and registers significant growth in the global acute-migraine treatment market, due to the increasing demand for effective treatment for acute migraine and the adoption of new therapies along with favorable reimbursement scenarios. Asia Pacific market is primarily driven by factors such as increasing expenditure on healthcare systems, improvement in the healthcare infrastructure, and growing awareness of disease. China is expected to register significant growth in the acute-migraine treatment market, due to growing population, low cost of drug and treatment, availability of drugs for the acute migraine treatment. Due to a lack of developed healthcare facilities, Latin America and the Middle East & Africa are projected to show sluggish growth in the Global Acute Migraine Treatment Industry.
Acute Migraine Treatment: Key Players
Some of the key players present in the Global Acute Migraine Treatment Industry are Amgen, Pfizer Inc., Hoffmann-La Roche Ltd, Eli Lily and Company, Novartis AG, Johnson and Johnson, Merck & Co., AstraZeneca and Teva Pharmaceutical among others.
Acute Migraine Treatment: Segmentation
The Global Acute Migraine Treatment Industry is segmented based on drug type, distribution channel, and geography.
Segmentation by Drug Type
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Triptans
- Dihydroergotamine
- Nonspecific Migraine Medications
- Analgesics
Segmentation by Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Drug Stores
- E-Commerce
Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/9324
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
